FDA Brief

Warning letters Drugs

FDA warning letter to

Kaleido Biosciences, Inc.

High riskIssued Aug 26, 2021Posted Sep 7, 2021Center for Drug Evaluation and Research | CDER

Kaleido Biosciences ran COVID-19 clinical trials of KB109 without required IND, FDA says.

What happened

FDA inspected Kaleido from February 24 to March 3, 2021, as sponsor of two clinical investigations of KB109 in non-hospitalized patients with mild-to-moderate COVID-19. FDA found Kaleido initiated and conducted Protocols K031-120 and K032-120 without submitting an IND (an investigational new drug application) or having one in effect; 350 subjects were randomized in K031-120 and 49 in K032-120. Kaleido argued KB109 was a food, but FDA concluded the study endpoints showed KB109 was intended to treat or mitigate COVID-19 and was therefore a drug.

What FDA found

  1. Kaleido started Protocols K031-120 and K032-120 without submitting an IND or having one in effect.

    21 CFR 312.20(a), 312.20(b), 312.40(a)
  2. FDA determined KB109 was intended to treat or mitigate COVID-19 in the studies, so it was a drug requiring an IND rather than a food.

    FD&C Act section 201(g)(1) [21 U.S.C. 321(g)(1)]

What FDA wants

Within 15 business days of receipt, notify FDA in writing of actions taken to prevent similar violations. If Kaleido believes it complied, include its reasoning and supporting information.

Who should pay attention

  • sponsors running COVID-19 drug trials
  • clinical trial sites enrolling subjects
  • companies classifying products as food, medical food, or drug

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk
  2. Prodrome Sciences USA, LLC

    Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.

    High risk
  3. Pamela K. Den Besten, DDS, MS

    FDA warned sponsor-investigator Pamela K. Den Besten for running a pediatric dental gel study without an IND, enrolling 43 subjects.

    High risk
  4. American Behavioral Research Institute, LLC

    FDA warned American Behavioral Research Institute for running a 40-subject Relaxium sleep study without an IND, treating a supplement as a drug.

    High risk